Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics

Casado‐Vela, Juan; Cebrián, Arancha; Pulgar, María Teresa Gómez del; Lacal, Juan Carlos

doi:10.1007/s12094-011-0707-9

Cited by 34 publications

(31 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reduces the numbers of patients needed to demonstrate differences between clinical phenotypes and effect of treatment, and is the strategy now being successfully implemented in several clinical studies, e.g. in respiratory [174,207], cardiovascular [208], infectious [209] and neurological [210] diseases, as well as cancer [211,212] and nephrology [213].…”

Section: Replicationmentioning

confidence: 99%

Application of ’omics technologies to biomarker discovery in inflammatory lung diseases

et al. 2013

View full text Add to dashboard Cite

Inflammatory lung diseases are highly complex in respect of pathogenesis and relationships between inflammation, clinical disease and response to treatment. Sophisticated large-scale analytical methods to quantify gene expression (transcriptomics), proteins (proteomics), lipids (lipidomics) and metabolites (metabolomics) in the lungs, blood and urine are now available to identify biomarkers that define disease in terms of combined clinical, physiological and patho-biological abnormalities. The aspiration is that these approaches will improve diagnosis, i.e. define pathological phenotypes, and facilitate the monitoring of disease and therapy, and also, unravel underlying molecular pathways. Biomarker studies can either select predefined biomarker(s) measured by specific methods or apply an ''unbiased'' approach involving detection platforms that are indiscriminate in focus. This article reviews the technologies presently available to study biomarkers of lung disease within the 'omics field. The contributions of the individual 'omics analytical platforms to the field of respiratory diseases are summarised, with the goal of providing background on their respective abilities to contribute to systems medicine-based studies of lung disease. @ERSpublications Summary of the application of 'omics-based analytical platforms for biomarker discovery in inflammatory lung diseases

show abstract

Section: Replicationmentioning

confidence: 99%

Application of ’omics technologies to biomarker discovery in inflammatory lung diseases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The remarkable complexity and heterogeneity of cells within an individual tumor has been elegantly demonstrated by sequence analyses of cancer cell genomes [1] and other post-genome era techniques, such as metabolomic and proteomic techniques largely based on mass spectrometry [3,4]. These findings highlight the various functionally important cell types within any given tumor, including cancer cells [5,6], cancer stem cells (CSCs) [7], stromal cells [8,9], vascular endothelium [10,11], and immunocytes [12], among others.…”

Section: Capturing Complexity In Carcinogenesismentioning

confidence: 99%

Toponome imaging system: multiplex biomarkers in oncology

Evans

Naidu

Rajpoot

et al. 2012

Trends in Molecular Medicine

View full text Add to dashboard Cite

“…For example the concentration of melatonin in urine of patients with migraine is more valuable than its plasma concentration. As a result, assessment of concentration of urine and plasma melatonin were considered as confirmed and probable biomarker, respectively (Loder et al, 2006), and (iii) the levels of some these biomarkers in each person or in each attack are not varied similarly, therefore it seems that contemporary investigation of proteome or metabolome profile in migrainous patients, as has been employed for other conditions such as cancer (Casado-Vela et al, 2011), is necessary.…”

Section: Practical Considerationsmentioning

confidence: 99%